Conference call and webcast to be held at 4:30 p.m. EDT
NEW HAVEN, Conn., Aug. 3, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and prurigo nodularis, today announced that senior management will host a conference call and live audio webcast on Thursday, August 10, 2023, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the second quarter ended June 30, 2023.
Read more at prnewswire.com